Avi Nandi is the Chief Technical Officer at The Center for Breakthrough Medicines. He has 15+ years of industry experience in gene therapy, viral vectors, and vaccines, with an MS in biology and an MBA, and he has contributed to the regulatory approval of ZOLGENSMA in United States and 10+ in Rest of World markets. Avi supported a pipeline of 15+ gene therapy products in development from preclinical to phase III development and led development and implementation of four gene therapy manufacturing processes across four GMP and three laboratory sites. He also has 10+ years of experience in vaccine and viral vector development, including AAV, adenovirus, herpesvirus, alphavirus, lentivirus, and RNA. His past experiences include: AveXis / Novartis Gene Therapies – head of technical development; Seqirus / CSL – head of virology and cell culture, process and product development lead; Novartis Vaccines and Diagnostics – technical development scientist, R&D microbial and molecular scientist; and Harvard Medical School – viral pathogenesis scientist.
